AUSTIN, Texas & CAMBRIDGE, Mass.--(BUSINESS WIRE)--
Genprex, Inc. (NASDAQ: GNPX), a clinical-stage gene therapy company developing a new approach to treating cancer based upon a novel proprietary technology platform, today announced that its President and Chief Operating Officer, Julien Pham, MD, MPH, will deliver a presentation about the company’s unique, leading-edge gene therapies and will also participate in a discussion panel on the topic of “Novel Therapies at the Cutting Edge of Cancer Research” at NobleConXV - Noble Capital Markets’ Fifteenth Annual Investor Conference at the W Hotel in Fort Lauderdale, Florida.
Genprex’s NobleConXV Presentation:
Presentation – The
Genprex Platform: A Novel Approach to Cancer Treatment
Date:
Monday, January 28, 2019
Time: 2 p.m. (EST)
Room:
Studio 1
Venue: W Hotel, 401 N Fort Lauderdale Beach Blvd,
Fort Lauderdale, FL 33304
Genprex’s NobleConXV Panel Discussion:
Panel Presentation
- Novel Therapies at the Cutting Edge of Cancer Research
Date:
Monday, January 28, 2019
Time: 5:30 p.m. (EST)
Room:
Studio 3
Venue: W Hotel, 401 N Fort Lauderdale Beach Blvd,
Fort Lauderdale, FL 33304
“We are honored to deliver a presentation about our cutting-edge technologies that have the potential to change the way cancer patients are treated,” said Rodney Varner, Genprex’s Chief Executive Officer and Chairman. “NobleCon is the perfect place to showcase the science behind this innovative approach to gene therapy.”
Genprex’s approach to treating cancer is based on a proprietary technology platform that includes the company’s initial product candidate, Oncoprex™ immunogene therapy. Oncoprex’s multimodal mechanism of action has demonstrated the ability to interrupt cell-signaling pathways that cause replication and proliferation of cancer cells, while re-establishing pathways for apoptosis, or programmed cell death, in cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. The company holds a portfolio of 30 issued patents and two pending patents covering its platform technologies.
Genprex is looking forward to presenting to the conference and will have a high-definition webcast of the presentation available the following day on the company's website at . It will also be available as part of a complete catalog of presentations available at Noble Capital Markets’ Conference website at as well as the new investor portal created by Noble called Channelchek at . The webcast will be archived on the company’s website, the NobleCon website and on Channelchek.com for 90 days following the event.
About Genprex, Inc.
Genprex, Inc. is a clinical stage gene therapy company developing potentially life-changing technologies for cancer patients, based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities. Oncoprex has a multimodal mechanism of action whereby it interrupts cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis, or programmed cell death, in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance. Visit the company’s web site at or follow Genprex on , and .
About Noble Capital Markets, Inc.
2019 marks Noble Capital Markets’ 35th anniversary. The Company is an equity-research driven, full-service, investment & merchant banking boutique focused on emerging growth companies. In addition to NobleCon, Noble hosts numerous “non-deal” corporate road shows across the United States and Canada. In late 2018, Noble launched Channelchek.com which features advanced market data, institutional-quality research, balanced news, videos and podcasts covering more than 6,000 emerging growth companies. There is no cost for investors to join. Members: FINRA, SIPC, MSRB.
Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Such statements include, but are not limited to, statements regarding the effects of Oncoprex or TUSC2 on cancer, and statements regarding the synergies obtained by combining Oncoprex with EGFR inhibitors and checkpoint inhibitors. Risks that contribute to the uncertain nature of the forward-looking statements include the presence and level of TUSC2’s effect on cancer, as well as the timing and success of our clinical trials and planned clinical trials of TUSC2 and Oncoprex and our other potential product candidates and the timing and success of obtaining FDA approval of Oncoprex and our other potential product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in our filings and reports with the United States Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. We undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.
View source version on businesswire.com:
